Biogenerics, otherwise known as biosimilars or follow-on biologics, have taken center stage during the healthcare reform debate. There is a number of ‘factions’ arguing their position as to how these generic variations of biologic therapies should be protected by patent exclusivity.
BIO, National Venture Capital Association, American Enterprise Institute and the American Intellectual Property Law Association are all in favor of a longer term. And, patient advocacy groups and generic drug makers are arguing the opposite trying to open up as much competition as possible to lower drug prices. Obviously, the companies themselves are voicing their opinion that their R&D costs are high and that they need exclusive marketing rights in order to recoup their investment.
One Senate Committee has already approved a recommended 12-year exclusive license. The Obama administration is pushing for 7 years. Other (unreasonable) challengers are arguing it should be 5 years or less.
In this video, CEO John Lechleiter of Lilly makes a very strong case for why we cannot allow this decision to stifle innovation across the life sciences industry.
